Category Archives: MS Treatment

The potential of the cheap cholesterol-lowering drug simvastatin as a treatment option for multiple sclerosis is to be investigated in a phase III trial involving more than 1,000 patients. The trial will be led by Jeremy Chataway, a researcher at the UCL Institute of Neurology, who conducted a previous smaller phase II trial, the results of which were published in The Lancet[1] in 2014 and suggested that simvastatin appeared to be a treatment option worthy of further investigation. The phase III trial will involve 1180 patients with secondary progressive MS, for which there are currently no licensed treatments that can slow or stop disability progression, who will be recruited by 30 centres across the UK. The trial will take six years to complete, with the first patients receiving treatment later this year. Chataway said: This drug holds incredible promise for the thousands of people living with secondary progressive MS in the UK, and around the world, who currently have few options for treatments that have an effect on disability. This study will establish definitively whether simvastatin is able to slow the rate of disability progression over a three-year period, and we are very hopeful it will. In the two-year phase … Continue reading →

Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis -- considered a key step in managing the debilitating disease. The Swiss drugmaker wants to find compelling science in whats called remyelination, or repairing the protective sheath around nerve cells, according to Sanjay Keswani, the Basel-based head of neuroscience, opthalmology and rare diseases at Roches pharma research and early development group. Roche also has its own portfolio of experimental remyelinationcompounds, though none have reached human trials. The most important business stories of the day. Get Bloomberg's daily newsletter. The worlds biggest maker of cancer therapies aims to expand its portfolio of multiple sclerosis treatments to tap into a market thats projected to grow to $24 billion by 2020. Roche won its foothold in March, when it won U.S. approval for Ocrevus, a potential blockbuster thats likely to be the only option for patients with a particular form of MS. In remyelination, Roche will have to catch up with Biogen Inc., which is already conducting human tests on its drug candidate. Frankly, we are currently looking at everything, Keswani said in an interview on Tuesday. Whats important … Continue reading →

Potential risks of common MS treatment Science Daily The study aimed to identify potential adverse events related to beta-interferon treatment for relapsing-remitting multiple sclerosis by analyzing health records of over 2,000 British Columbians with multiple sclerosis between 1995 and 2008. "Once a ... and more » More: Potential risks of common MS treatment - Science Daily … Continue reading →

Health Beat: Multiple sclerosis drug... COLUMBUS, Ohio - For 25 years, Pamela Arterbridge has been building her salon business, one customer at a time. "I have a dedicated clientele and I never wanted to let them down," Arterbridge said. But four years ago, she began feeling exhausted and then some symptoms she couldn't ignore. "I woke up one morning and all of my toes were numb and tingling, and it felt like I had rocks in my shoes," described Arterbridge. She had multiple sclerosis. "I have a lesion on my spine, and I have three on my brain," Arterbridge detailed. Dr. Michael Racke, a neurologist at The Ohio State University's Wexner Medical Center in Columbus, Ohio, is an expert in MS and one of a nationwide team of researchers studying the effects of ocrelizumab. "Almost half the patients had no evidence of disease activity in terms of their MS," Racke said. "That's much higher than we've seen with any other MS treatment." Ocrelizumab is also the first drug ever available for the primary, progressive form of the disease, which includes about 15 percent of MS patients. The drug is given to all MS patients as an infusion. Research summary - … Continue reading →

A UCL researcher is leading a phase 3 trial involving more than 1,000 people with multiple sclerosis (MS) to investigate whether simvastatin could become a treatment for the condition. The project will cost almost 6 million and is being funded by collaboration between the National Institute for Health Research (NIHR), the MS Society (UK), the National MS Society (US), the NHS and UK universities. The trial will test simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. There are currently no licensed treatments that can slow or stop disability progression in people with this type of MS. The research will be led by Dr Jeremy Chataway (UCL Institute of Neurology), who led the phase 2 trial into simvastatin that was published inThe Lancetin 2014. It involved 140 people with secondary progressive MS. The research found those taking high doses of the drug had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of study. Dr Chataway said: "This drug holds incredible promise for the thousands of people living with secondary progressive MS in the UK, and around the world, who … Continue reading →

Welcome to the practice of Dr. David Williams, a leading periodontist in Pensacola, FL specializing in state of the art, minimally invasive treatments for gum disease, cosmetic periodontal surgery, dental implants, and other procedures to make your teeth and gums healthy and attractive. When your smile looks good, you feel good. A healthy, attractive smile projects good overall health, increases confidence, and gives you the freedom to enjoy life without worry or embarrassment about how your smile appears to others. When it comes to treating missing teeth, gum disease, receding gums, unsightly or damaged teeth, and other periodontal problems, most patients want a contemporary, highly skilled, and dependable periodontist in Pensacola, FL that they can trust, someone who stays ahead of the curve in periodontal surgery and is enthusiastic about providing only the best and latest treatments available. Our patients and referring dentists routinely report a high grade of satisfaction with the periodontal care received from Dr. Williams, as he consistently provides successful results. Go here to see the original: Periodontist in Pensacola, FL - Gum Disease Treatment ... … Continue reading →

rG(ObXF]iWpfK-JVN2H*G hY5 $QcH%7qScA-@r:jYdX>a.%:kyz" /wPLIdXNc $wTP-c$ bBLD$z]?~K%S;A *&0iS#YV6C2Ro:rw9/IAESlb&>o/OdI6k?4GBzl4|u; 3$'=Jgh(.L-*}VYkNfS 8(?jza~d6^f#6/!*ILp@g&(LALczrw0bL$-al>En^Km/Pt}?_2Qdm!_3V qKvP]$iq((5;%wA){iFKonQ4oBS6R;FPo4MyWoyzir_fvXXV^ o=Q{;IwCo@5fn8bk|Dhw{ ]v~I)aP4rQm+7a J@ np+a*9i e7v`6 '7];KXL=9Zar`$2E5Z,#]9ARL8`w C0HHHq(&D>$ka`I@plQbVDn5HU,T~!B]{I … Continue reading →

May 9, 2017 A UCL researcher is leading a phase 3 trial involving more than 1,000 people with multiple sclerosis (MS) to investigate whether simvastatin could become a treatment for the condition. The project will cost almost 6 million and is being funded by collaboration between the National Institute for Health Research (NIHR), the MS Society (UK), the National MS Society (US), the NHS and UK universities. The trial will test simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. There are currently no licensed treatments that can slow or stop disability progression in people with this type of MS. The research will be led by Dr Jeremy Chataway (UCL Institute of Neurology), who led the phase 2 trial into simvastatin that was published in The Lancet in 2014. It involved 140 people with secondary progressive MS. The research found those taking high doses of the drug had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of study. Dr Chataway said: "This drug holds incredible promise for the thousands of people living with secondary progressive MS in the UK, … Continue reading →

Statinscould soon be prescribed to treat multiple sclerosis after a groundbreaking trial began to see if the cheap cholesterol busting drug could delay symptoms. The 6 million projectis being led by University College London and involves 1,180 people at 30 centres across Britain. It follows a successful small trial in 2014 which showed a significant reduction in the rate of brain shrinkage and an increase in mobility after two years for people on high doses of simvastatin , which usually prescribed to lower cholesterol. Charities said the trial was a 'momentous step' forward which offered hope to thousands of people with relapsing MS. The trial is scheduled to last six years, but because statins are already known to be safe and widely used, the treatment would quickly pass through regulators if it was deemed to be successful. Lead researcher Dr Jeremy Chataway from University College London's Institute of Neurology, who led an earlier study into the drug, said: "This drug holds incredible promise for the thousands of people living with secondary progressive MS in the UK, and around the world, who currently have few options for treatments that have an effect on disability. "This study will establish definitively whether simvastatin … Continue reading →

The FDA has approved a new drug to treat people living with multiple sclerosis. The chronic auto-immune disorder causes a patients own system to attack his or her brain and spinal cord. The drug is not a cure for MS, but the treatment will allow some patients to live virtually symptom-free for the first time in years. For 25 years, Pamela Arterbridge has been building her salon business one customer at a time. Pamela said, I have a dedicated clientele and I never wanted to let them down. Four years ago, she began feeling exhausted and developed symptoms she couldnt ignore. I woke up one morning and all of my toes were numb and tingling and it felt like I had rocks in my shoes, said Pamela. She had multiple sclerosis. I have a lesion on my spine, and I have three on my brain, added Pamela. Neurologist Michael Racke is an expert on MS at Ohio States Wexner Medical Center. He is one of a nationwide team of researchers studying the effects of a drug called Ocrelizumab. Almost half the patients had no evidence of disease activity in terms of their MS," said Dr. Racke. "Thats much higher than … Continue reading →